Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Change in Account Payables: 2013-2024

Historic Change in Account Payables for ImmunityBio (IBRX) over the last 12 years, with Dec 2024 value amounting to -$3.2 million.

  • ImmunityBio's Change in Account Payables rose 84.40% to -$1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.4 million, marking a year-over-year decrease of 54.88%. This contributed to the annual value of -$3.2 million for FY2024, which is 51.10% up from last year.
  • According to the latest figures from FY2024, ImmunityBio's Change in Account Payables is -$3.2 million, which was up 51.10% from -$6.5 million recorded in FY2023.
  • ImmunityBio's 5-year Change in Account Payables high stood at $8.0 million for FY2022, and its period low was -$6.5 million during FY2023.
  • Moreover, its 3-year median value for Change in Account Payables was -$3.2 million (2024), whereas its average is -$547,667.
  • In the last 5 years, ImmunityBio's Change in Account Payables plummeted by 244.63% in 2021 and then skyrocketed by 315.23% in 2022.
  • ImmunityBio's Change in Account Payables (Yearly) stood at $2.6 million in 2020, then tumbled by 244.63% to -$3.7 million in 2021, then skyrocketed by 315.23% to $8.0 million in 2022, then slumped by 180.95% to -$6.5 million in 2023, then surged by 51.10% to -$3.2 million in 2024.